JPWO2023229032A1 - - Google Patents
Info
- Publication number
- JPWO2023229032A1 JPWO2023229032A1 JP2024523363A JP2024523363A JPWO2023229032A1 JP WO2023229032 A1 JPWO2023229032 A1 JP WO2023229032A1 JP 2024523363 A JP2024523363 A JP 2024523363A JP 2024523363 A JP2024523363 A JP 2024523363A JP WO2023229032 A1 JPWO2023229032 A1 JP WO2023229032A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022087166 | 2022-05-27 | ||
| PCT/JP2023/019755 WO2023229032A1 (ja) | 2022-05-27 | 2023-05-26 | 免疫チェックポイント阻害剤に対して治療抵抗性を示すがんの治療薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2023229032A1 true JPWO2023229032A1 (cg-RX-API-DMAC7.html) | 2023-11-30 |
| JPWO2023229032A5 JPWO2023229032A5 (cg-RX-API-DMAC7.html) | 2026-06-02 |
Family
ID=88919516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024523363A Pending JPWO2023229032A1 (cg-RX-API-DMAC7.html) | 2022-05-27 | 2023-05-26 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250352541A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4534100A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JPWO2023229032A1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN119403571A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023229032A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4347582A4 (en) | 2021-05-27 | 2025-05-07 | Boundless Bio, Inc. | CHECKPOINT KINASE-1 INHIBITORS AND USES THEREOF |
| EP4626433A1 (en) * | 2022-11-29 | 2025-10-08 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitors combinations and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8850801A1 (es) * | 2008-12-17 | 2010-07-27 | Lilly Co Eli | Compuestos útiles para inhibir chk1 |
| JO3145B1 (ar) * | 2010-11-08 | 2017-09-20 | Lilly Co Eli | مركبات مفيدة لتثبيط chk1 |
| GB201402277D0 (en) * | 2014-02-10 | 2014-03-26 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| CA3013514C (en) * | 2016-02-04 | 2021-11-23 | Pharmaengine, Inc. | 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications |
| CA3135165A1 (en) * | 2019-03-28 | 2020-10-01 | Sierra Oncology, Inc. | Methods of treating cancer with chk1 inhibitors |
| US12404332B2 (en) * | 2020-03-13 | 2025-09-02 | Research Development Foundation | Methods for diagnosing and treating cancers |
| MX2023006364A (es) * | 2020-11-30 | 2023-06-13 | Sumitomo Pharma Co Ltd | Derivado de 5-heteroaril-1h-pirazol-3-amina. |
-
2023
- 2023-05-26 JP JP2024523363A patent/JPWO2023229032A1/ja active Pending
- 2023-05-26 WO PCT/JP2023/019755 patent/WO2023229032A1/ja not_active Ceased
- 2023-05-26 US US18/867,830 patent/US20250352541A1/en active Pending
- 2023-05-26 EP EP23811904.4A patent/EP4534100A4/en active Pending
- 2023-05-26 CN CN202380043023.8A patent/CN119403571A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250352541A1 (en) | 2025-11-20 |
| CN119403571A (zh) | 2025-02-07 |
| EP4534100A4 (en) | 2026-05-20 |
| EP4534100A1 (en) | 2025-04-09 |
| WO2023229032A1 (ja) | 2023-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR102023005164A2 (cg-RX-API-DMAC7.html) | ||
| BR102022025291A2 (cg-RX-API-DMAC7.html) | ||
| BR112025024041B1 (pt) | Elemento de despejamento para uma embalagem compósita e embalagem compósita com um elemento de despejamento | |
| BR112025020304B1 (pt) | Liga de solda, esfera de solda, pré-forma de solda, junta de solda e circuito | |
| BR112025008516B1 (pt) | Método tudo em um de recuperação de níquel para recuperar níquel a partir de matérias-primas contendo níquel | |
| BR112025016688B1 (pt) | Compostos e composições farmacêuticas | |
| BR112025011041B1 (pt) | Dispositivo para inspeção de um elemento roscado e método de inspeção correspondente | |
| BR112024022558B1 (pt) | Polipeptídeo, polinucleotídeo, ácido nucleico, vetor, célula hospedeira, método para produzir o polipeptídeo, composição, e, método in vitro para aumentar adesão celular | |
| BR112025005915B1 (pt) | Gerador, dispositivo e método de ablação de campo pulsado | |
| BR112025005363B1 (pt) | Equipamento de usuário, entidade de rede e métodos relacionados | |
| BR102023016405B1 (pt) | Estrutura de viga de pá, pá de energia eólica e equipamento de energia eólica | |
| BR112024026850B1 (pt) | Triturador de mandíbula e método de serviço ou de manutenção de um triturador de mandíbula | |
| BR112024025233B1 (pt) | Método para alterar o estado de elevação vertical para um veículo transportador, controle e veículo | |
| BR102023009702B1 (pt) | Dispositivo para alisamento e aplicação de substância de tratamento | |
| BR112024019620B1 (pt) | Derivados de 2-[(2-oxo-4-fenil-2h-cromen-7-il)óxi]propanamido, composições farmacêuticas e usos | |
| BR112024027500B1 (pt) | Polipeptídeo, ácido nucleico, vetor, célula hospedeira, método para produzir o polipeptídeo, composição, uso do polipeptídeo, e, método para promover a proliferação de uma célula in vitro | |
| BR102023002997B1 (pt) | Um aparelho para detecção de vazamento de um gás e um método e um sistema do mesmo | |
| BR112024018530B1 (pt) | Método para determinar nível de escória do alto-forno, método para operar alto-forno e unidade de controle | |
| BR112024027130B1 (pt) | Sistema e método para um conjunto de cuff (balão) de tubo endotraqueal | |
| BR112025001284B1 (pt) | Cabo, sistema de sensor e método de montagem de um alojamento de sensor | |
| BR102022024748B1 (pt) | Equipamento extrator de esporos da superfície de grãos de cereal para aplicação em laboratório e seu processo operacional | |
| BR102022023712B1 (pt) | Sistema de montagem de estrutura flexível para estufas agrícolas, com sistema molejante de movimentação em relação à ação dos ventos | |
| BR122025008970A2 (pt) | Método para decodificar um vídeo, sistema e mídia legível por computador | |
| BR122025008972A2 (pt) | Sistema, método para decodificar um vídeo e mídia legível por computador | |
| BR122025008973A2 (pt) | Sistema, método para decodificar um vídeo e mídia legível por computador |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260525 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260525 |